Skip to main content
NCBI home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1981;59(3):427–437.

Toxicology of the 8-aminoquinolines and genetic factors associated with their toxicity in man*

P E Carson, R Hohl, M V Nora, G W Parkhurst, T Ahmad, S Scanlan, H Frischer
PMCID: PMC2396066  PMID: 6976850

Abstract

In vitro studies on primaquine have been carried out to examine its ability to stimulate the oxidative pathway of glucose metabolism in human erythrocytes and in vivo studies were carried out after ingestion of the drug to determine plasma levels and to investigate the formation of metabolites and the effects of the drug on human erythrocytes. These investigations showed that:

1) Two mechanisms are involved in the stimulation of the oxidative pathway. This was demonstrated by comparing the effects of methylene blue, ascorbic acid, primaquine, and other drugs on normal, glutathione-reductase-deficient, and G6PD-deficient erythrocytes. A start was made towards classifying drugs according to the mechanism by which they stimulate CO2 production.

2) Following oral ingestion of primaquine, three as yet unidentified metabolites were present, two in the plasma and one in the urine. The rapid disappearance of primaquine from the plasma (within 24 hours) was confirmed.

3) Two factors that stimulate glucose oxidation in human erythrocytes were found in plasma; one occurred only in fresh plasma, when EDTA was present, and the other occurred in all plasma and serum samples studied.

4) The erythrocytes of blood drawn 24 hours after the ingestion of primaquine (after primaquine had disappeared from the plasma) showed increased ability to oxidize glucose.

It is not yet known whether serum or plasma prepared from blood drawn 24 hours after ingestion of primaquine has the ability to increase the oxidation of glucose.

Full text

PDF
427

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALVING A. S., ARNOLD J., HOCKWALD R. S., CLAYMAN C. B., DERN R. J., BEUTLER E., FLANAGAN C. L. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med. 1955 Aug;46(2):301–306. [PubMed] [Google Scholar]
  2. ALVING A. S., CARSON P. E., FLANAGAN C. L., ICKES C. E. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science. 1956 Sep 14;124(3220):484–485. doi: 10.1126/science.124.3220.484-a. [DOI] [PubMed] [Google Scholar]
  3. ALVING A. S., JOHNSON C. F., TARLOV A. R., BREWER G. J., KELLERMEYER R. W., CARSON P. E. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Piasmodium vivax by intermittent regimens of drug administration: a preliminary report. Bull World Health Organ. 1960;22:621–631. [PMC free article] [PubMed] [Google Scholar]
  4. Carson P. E., Frischer H. Glucose-6-phosphate dehydrogenase deficiency and related disorders of the pentose phosphate pathway. Am J Med. 1966 Nov;41(5):744–761. doi: 10.1016/0002-9343(66)90035-0. [DOI] [PubMed] [Google Scholar]
  5. Craige B., Eichelberger L., Jones R., Alving A. S., Pullman T. N., Whorton C. M. THE TOXICITY OF LARGE DOSES OF PENTAQUINE (SN-13,276), A NEW ANTIMALARIAL DRUG. J Clin Invest. 1948 May;27(3 Pt 2):17–24. doi: 10.1172/JCI101955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Frischer H., Ahmad T. Severe generalized glutathione reductase deficiency after antitumor chemotherapy with BCNU" [1,3-bis(chloroethyl)-1-nitrosourea]. J Lab Clin Med. 1977 May;89(5):1080–1091. [PubMed] [Google Scholar]
  7. Frischer H., Bowman J. Hemoglobin E, an oxidatively unstable mutation. J Lab Clin Med. 1975 Apr;85(4):531–539. [PubMed] [Google Scholar]
  8. Frischer H. Erythrocytic glutathione reductase deficiency in a hospital population in the United States. Am J Hematol. 1977;2(4):327–334. doi: 10.1002/ajh.2830020402. [DOI] [PubMed] [Google Scholar]
  9. Gaetani G. D., Mareni C., Ravazzolo R., Salvidio E. Haemolytic effect of two sulphonamides evaluated by a new method. Br J Haematol. 1976 Feb;32(2):183–191. doi: 10.1111/j.1365-2141.1976.tb00921.x. [DOI] [PubMed] [Google Scholar]
  10. Greaves J., Price-Evans D. A., Gilles H. M., Baty J. D. A selected ion monitoring assay for primaquine in plasma and urine. Biomed Mass Spectrom. 1979 Mar;6(3):109–112. doi: 10.1002/bms.1200060306. [DOI] [PubMed] [Google Scholar]
  11. Jones R., Craige B., Alving A. S., Whorton C. M., Pullman T. N., Eichelberger L. A STUDY OF THE PROPHYLACTIC EFFECTIVENESS OF SEVERAL 8-AMINOQUINOLINES IN SPOROZOITE-INDUCED VIVAX MALARIA (CHESSON STRAIN). J Clin Invest. 1948 May;27(3 Pt 2):6–11. doi: 10.1172/JCI101973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jones R., Pullman T. N., Whorton C. M., Craige B., Alving A. S., Eichelberger L. THE THERAPEUTIC EFFECTIVENESS OF LARGE DOSES OF PALUDRINE IN ACUTE ATTACKS OF SPOROZOITE-INDUCED VIV AX MALARIA (CHESSON STRAIN). J Clin Invest. 1948 May;27(3 Pt 2):51–55. doi: 10.1172/JCI101971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. McNamara J. V., Eppes R. B., Powell R. D., Carson P. E. The effects of para-aminobenzoic acid on the hemolytic effects of 4, 4'-diaminodiphenylsulfone. Mil Med. 1966 Sep;131(9 Suppl):1057–1060. [PubMed] [Google Scholar]
  14. Sagone A. L., Jr, Burton G. M. The effect of BCNU and adriamycin on normal and G6PD deficient erythrocytes. Am J Hematol. 1979;7(2):97–106. doi: 10.1002/ajh.2830070202. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES